-
-
关键词:
- 家族遗传性卵巢癌 诊断 治疗 专家共识
-
表 1 降低风险手术的建议年龄
基因 卵巢癌风险 RRSO手术建议年龄（岁） BRCA1 增加 35～40 BRCA2 增加 40～45 BRIP-1 增加 45～50 RAD51C 增加 45～50 RAD51D 增加 45～50 MSH1，MLH1，MSH6，PMS2，EPCAM 增加 因同时增加子宫内膜癌的风险，推荐完成生育后，
同时切除子宫及双侧输卵管-卵巢STK11 增加患非上皮型卵巢癌风险 暂无推荐 ATM 可能增加 证据不充足 NBN 可能增加 证据不充足 PALB-2 可能增加 证据不充足 
下载: 导出CSV
-
[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33. doi: 10.3322/caac.21654 [2] Samadder NJ, Giridhar KV, Baffy N, et al. Hereditary cancer syndromes-a primer on diagnosis and management: part 1: breast-ovarian cancer syndromes[J]. Mayo Clin Proc, 2019, 94(6):1084-1098. doi: 10.1016/j.mayocp.2019.02.017 [3] Piombino C, Cortesi L, Lambertini M, et al. Secondary prevention in hereditary breast and/or ovarian cancer syndromes other than BRCA[J]. J Oncol, 2020, 2020:6384190. [4] Santana Dos Santos E, Lallemand F, Petitalot A, et al. HRness in breast and ovarian cancers[J]. Int J Mol Sci, 2020, 21(11):3850. doi: 10.3390/ijms21113850 [5] Lang GT, Shi JX, Hu X, et al. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2, 991 patients and 1, 043 controls by next-generation sequencing[J]. Int J Cancer, 2017, 141(1):129-142. doi: 10.1002/ijc.30692 [6] Couch FJ, Shimelis H, Hu C, et al. Associations between cancer predisposition testing panel genes and breast cancer[J]. JAMA Oncol, 2017, 3(9):1190-1196. doi: 10.1001/jamaoncol.2017.0424 [7] Cerretelli G, Ager A, Arends MJ, et al. Molecular pathology of Lynch syndrome[J]. J Pathol, 2020, 250(5):518-531. doi: 10.1002/path.5422 [8] Chung SH, Woldenberg N, Roth AR, et al. BRCA and beyond: comprehensive image-rich review of hereditary breast and gynecologic cancer syndromes[J]. Radiographics, 2020, 40(2):306-325. doi: 10.1148/rg.2020190084 [9] Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review[J]. Cancer Biol Med, 2017, 14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084 [10] Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021,19(1):77-102. [11] Russo A, Calo V, Bruno, et al. Hereditary ovarian cancer[J]. Crit Rev Oncol Hematol, 2009, 69(1):28-44. doi: 10.1016/j.critrevonc.2008.06.003 [12] Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA, 2017, 317(23):2402-2416. doi: 10.1001/jama.2017.7112 [13] Cui MH, Zhang XW, Yu T, et al. PMS2 germline mutation c. 1577delA (p. Asp526Alafs*69)-induced Lynch syndrome-associated endometrial cancer: A case report[J]. Medicine (Baltimore), 2019, 98(51):e18279. doi: 10.1097/MD.0000000000018279 [14] Woolderink JM, De Bock GH, de Hullu JA, et al. Characteristics of Lynch syndrome associated ovarian cancer[J]. Gynecol Oncol, 2018,150(2):324-330. [15] Moldovan R, Keating S, Clancy T. The impact of risk-reducing gynaecological surgery in premenopausal women at high risk of endometrial and ovarian cancer due to Lynch syndrome[J]. Fam Cancer, 2015, 14(1):51-60. doi: 10.1007/s10689-014-9761-0 [16] Ryan NAJ, Evans DG, Green K, et al. Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer[J]. Gynecol Oncol, 2017, 144(3):491-495. doi: 10.1016/j.ygyno.2017.01.005 [17] Tacheci I, Kopacova M, Bures J. Peutz-jeghers syndrome[J]. Curr Opin Gastroenterol, 2021, 37(3):245-254. doi: 10.1097/MOG.0000000000000718 [18] 中国抗癌协会妇科肿瘤专业委员会.卵巢恶性肿瘤诊断与治疗指南(2021年版)[J].中国癌症杂志,2021,31(6):490-500. [19] Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline[J]. J Clin Oncol, 2020, 38(11):1222-1245. [20] Palacios J, de la Hoya M, Bellosillo B, et al. Mutational screening of BRCA1/2 genes as a predictive factor for therapeutic response in epithelial ovarian cancer: a consensus guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH)[J]. Virchows Arch, 2020, 476(2):195-207. doi: 10.1007/s00428-019-02709-3 [21] Eoh KJ, Kim HM, Lee JY, et al. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer[J]. BMC Cancer, 2020, 20(1):204. doi: 10.1186/s12885-020-6693-y [22] Hereditary cancer syndromes and risk assessment: ACOG committee opinion, number 793[J]. Obstet Gynecol, 2019, 134(6):e143-e149. [23] Lu KH, Wood ME, Daniels M, et al. American society of clinical oncology expert statement: collection and use of a cancer family history for oncology providers[J]. J Clin Oncol, 2014, 32(8):833-840. [24] Cramer DW, Hutchison GB, Welch WR, et al. Factors affecting the association of oral contraceptives and ovarian cancer[J]. N Engl J Med, 1982, 307(17):1047-1051. doi: 10.1056/NEJM198210213071703 [25] Marchetti C, De Felice F, Palaia I, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers[J]. BMC Womens Health, 2014, 14:150. doi: 10.1186/s12905-014-0150-5 [26] Evans DG, Lalloo F, Ashcroft L, et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(8):2318-2324. doi: 10.1158/1055-9965.EPI-09-0171 [27] Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation[J]. J Clin Oncol, 2014, 32(15):1547-1553. doi: 10.1200/JCO.2013.53.2820 [28] Walker JL, Powell CB, Chen LM, et al. Society of gynecologic oncology recommendations for the prevention of ovarian cancer[J]. Cancer, 2015, 121(13):2108-2120. doi: 10.1002/cncr.29321 [29] ACOG Practice Bulletin No. 147: Lynch syndrome[J]. Obstet Gynecol, 2014, 124(5):1042-1054. [30] Vukovic P, Peccatori FA, Massarotti C, et al. Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variants[J]. Crit Rev Oncol Hematol, 2021, 157:103201. doi: 10.1016/j.critrevonc.2020.103201 [31] Turan V, Oktay K. BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging[J]. Hum Reprod Update, 2020, 26(1):43-57. [32] Son KA, Lee DY, Choi D. Association of BRCA mutations and anti-mullerian hormone level in young breast cancer patients[J]. Front Endocrinol (Lausanne), 2019, 10:235. doi: 10.3389/fendo.2019.00235 [33] Chapman JS, Powell CB, McLennan J, et al. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers[J]. Gynecol Oncol, 2011, 122(2):339-343. doi: 10.1016/j.ygyno.2011.04.004 [34] Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer[J]. N Engl J Med, 2019, 381(25):2391-2402. doi: 10.1056/NEJMoa1910962 [35] Farkkila A, Gulhan DC, Casado J, et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer[J]. Nat Commun, 2020, 11(1):1459. -
点击查看大图
表(1)
计量
- 文章访问数: 435
- HTML全文浏览量: 543
- PDF下载量: 318
- 被引次数: 0
